Kodiak Sciences Inc Common Stock (KOD) is a publicly traded Healthcare sector company. As of May 21, 2026, KOD trades at $36.85 with a market cap of $2.19B and a P/E ratio of -8.22. KOD moved +5.11% today. Year to date, KOD is +44.88%; over the trailing twelve months it is +792.12%. Its 52-week range spans $1.92 to $47.84. Analyst consensus is strong buy with an average price target of $62.67. Rallies surfaces KOD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kodiak’s KSI-101 Yields +17.8-Letter Gain, Spurs Phase 3 Asia Expansion: Kodiak’s KSI-101 achieved ≥15-letter gains in 58% of Asian MESI patients and a mean BCVA increase of +17.8 letters at Week 24, with central subfield thickness reduced below 325 µm after one injection. Consistent anatomic and visual outcomes in tertiary care and U.S. Phase 1b cohorts support Phase 3 PEAK and PINNACLE expansion into Asia.
| Metric | Value |
|---|---|
| Price | $36.85 |
| Market Cap | $2.19B |
| P/E Ratio | -8.22 |
| EPS | $-4.32 |
| Dividend Yield | 0.00% |
| 52-Week High | $47.84 |
| 52-Week Low | $1.92 |
| Volume | 213 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-229.97M |
| Gross Margin | 0.00% |
7 analysts cover KOD: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $62.67.